DR. JOEL MOSS, M.D., PH.D.
Osteopathic Medicine in Bethesda, MD
License number
Maryland D0016377
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
10 National Institutes Of Health BLDG 6D05, Bethesda, MD 20892
Phone
(301) 496-1597
(301) 496-2363 (Fax)
(301) 496-2363 (Fax)
Personal information
See more information about JOEL MOSS at radaris.comName
Address
Phone
8200 Wisconsin Ave APT 1002, Bethesda, MD 20814
8200 Wis, Bethesda, MD 20814
8200 Wis Ave, Bethesda, MD 20814
8200 Wisconsin Ave, Bethesda, MD 20814
Organization information
See more information about JOEL MOSS at bizstanding.comNih - Joel Moss MD
10 Ctr Dr BLDG 10, # 6D03, Bethesda, MD 20892
Categories:
Pulmonary & Respiratory Physicians & Surgeons
Phone:
(301) 496-1597 (Phone)
Professional information
Dr. Joel Moss, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
National Institutes Of Health, Bethesda 20892
(301) 496-1597 (Phone), (301) 496-2363 (Fax)
(301) 496-1597 (Phone), (301) 496-2363 (Fax)
Certifications:
Critical Care Medicine, 1987, Internal Medicine, 1975, Pulmonary Disease, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 1972
The Johns Hopkins Hospital
Natl Inst Hlth
New York University
Graduated: 1972
The Johns Hopkins Hospital
Natl Inst Hlth
Method For The Treatment Of Pulmonary Disease And Method Of Producing Proteins Of Use Therein
US Patent:
2012016, Jun 28, 2012
Filed:
Sep 8, 2010
Appl. No.:
13/394393
Inventors:
Joel Moss - Bethesda MD, US
Linda Stevens - Gaithersburg MD, US
Rodney L. Levine - Rockville MD, US
Linda Stevens - Gaithersburg MD, US
Rodney L. Levine - Rockville MD, US
International Classification:
A61K 38/45, C07K 14/47, C12P 21/02, A61K 38/17, A61P 11/00, A61P 11/06
US Classification:
424 945, 514 18, 514 17, 514 16, 514 15, 435 681, 514 11, 514 213, 530324
Abstract:
Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide. Methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a modified polypeptide (such as HNP-1) including at least one ornithine residue in place of an arginine residue are also disclosed.
Mammalian Guanine Nucleotide Binding Protein With An Adp-Rybosylation Factor Domain
US Patent:
5386021, Jan 31, 1995
Filed:
Apr 19, 1993
Appl. No.:
8/049473
Inventors:
Joel Moss - Bethesda MD
Koichi Mishima - Rockville MD
Maria S. Nightingale - Bethesda MD
Mikako Tsuchiya - Izumo, JP
Koichi Mishima - Rockville MD
Maria S. Nightingale - Bethesda MD
Mikako Tsuchiya - Izumo, JP
Assignee:
The United States of America, as represented by the Department of Health
& Human Services - Washington DC
& Human Services - Washington DC
International Classification:
C07H 1700
US Classification:
536 231
Abstract:
The invention provides a method for detecting the presence of ARD 1 protein in a sample. The method includes the steps of providing labeled or immobilized anti-ARD 1 antibody in a reaction zone, introducing sample into the reaction zone such that ARD 1 protein in the sample, if present, will react with said antibody to form an immunological complex, and detecting the formation of said immunological complex. Cells, nucleotide and amino acid sequences and vectors associated with ARD 1 are also described.
Tryptophan As A Functional Replacement For Adp-Ribose-Arginine In Recombinant Proteins
US Patent:
7923535, Apr 12, 2011
Filed:
Apr 24, 2009
Appl. No.:
12/430023
Inventors:
Joel Moss - Bethesda MD, US
Linda Stevens - Gaithersburg MD, US
Christelle Bourgeois - Bethesda MD, US
Rita Bortell - Shirley MA, US
Linda Stevens - Gaithersburg MD, US
Christelle Bourgeois - Bethesda MD, US
Rita Bortell - Shirley MA, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
University of Massachusetts - Boston MA
University of Massachusetts - Boston MA
International Classification:
A61K 39/00, A61K 39/38, C07K 14/00
US Classification:
530350, 4241841, 4241851
Abstract:
A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.
Clones Encoding Mammalian Adp-Ribosylarginine Hydrolases
US Patent:
5716816, Feb 10, 1998
Filed:
Jan 14, 1994
Appl. No.:
8/183214
Inventors:
Joel Moss - Bethesda MD
Sally J. Stanley - Silver Spring MD
Maria S. Nightingale - Bethesda MD
Lucia Monaco - Rome, IT
James J. Murtagh - Atlanta GA
Tatsuyuki Takada - Rockville MD
Sally J. Stanley - Silver Spring MD
Maria S. Nightingale - Bethesda MD
Lucia Monaco - Rome, IT
James J. Murtagh - Atlanta GA
Tatsuyuki Takada - Rockville MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
C12N 1555, C12N 1510, C12N 1563, C12N 924
US Classification:
4351723
Abstract:
The present invention relates to the production of mammalian ADP-ribosylarginine hydrolases. These enzymes can be manufactured using recombinant DNA technology and are useful in regulation of proteins involved in key metabolic pathways.
Adp-Ribosyl Acceptor Hydrolase 3 (Arh3) Polypeptides And Methods Of Use
US Patent:
7670806, Mar 2, 2010
Filed:
Mar 12, 2008
Appl. No.:
12/047185
Inventors:
Joel Moss - Bethesda MD, US
Shunya Oka - Niigata, JP
Jiro Kato - Rockville MD, US
Jianfeng Zhu - Frederick MD, US
Atsushi Kasamatsu - Rockville MD, US
Shunya Oka - Niigata, JP
Jiro Kato - Rockville MD, US
Jianfeng Zhu - Frederick MD, US
Atsushi Kasamatsu - Rockville MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12P 19/00, C12N 9/00, C12N 1/20, C12N 15/00, C07H 21/04
US Classification:
435 72, 435183, 4352523, 4353201, 536 232
Abstract:
This disclosure provides methods for catalyzing the release of ADP-ribose from poly(ADP-ribose) or O-acetyl-ADP-ribose. Also provided are methods for modifying DNA repair or chromatin structure by introducing into the cell an agent that modifies the activity of an ARH3 polypeptide, or variant or fragment thereof. Further provided are methods for screening molecules involved in the poly(ADP-ribosyl)ation of proteins or O-acetyl-ADP-ribose content, and method for treating disorders by altering activity of an ARH3 protein.
Tryptophan As A Functional Replacement For Adp-Ribose-Arginine In Recombinant Proteins
US Patent:
7541139, Jun 2, 2009
Filed:
Jun 27, 2003
Appl. No.:
10/517565
Inventors:
Joel Moss - Bethesda MD, US
Linda Stevens - Gaithersburg MD, US
Christelle Bourgeois - Bethesda MD, US
Rita Bortell - Shirley MA, US
Linda Stevens - Gaithersburg MD, US
Christelle Bourgeois - Bethesda MD, US
Rita Bortell - Shirley MA, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
University of Massachusetts - Boston MA
University of Massachusetts - Boston MA
International Classification:
C12N 15/00, C12P 1/00, C12Q 1/00
US Classification:
435 4, 435 41, 435440
Abstract:
A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.
Mammalian Muscle Nad: Arginine Adp-Ribosyltransferase
US Patent:
5834310, Nov 10, 1998
Filed:
Jul 18, 1997
Appl. No.:
8/896410
Inventors:
Joel Moss - Bethesda MD
Ian Okazaki - Rockville MD
Anna Zolkiewska - Rockville MD
Maria S. Nightingale - Bethesda MD
Ian Okazaki - Rockville MD
Anna Zolkiewska - Rockville MD
Maria S. Nightingale - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
C12N 120, C07H 2104
US Classification:
435325
Abstract:
This invention relates to the identification and molecular characterization of NAD:arginine ADP-ribosyltransferases. Sequences from the rabbit skeletal muscle NAD:arginine ADP-ribosyltransferase and the human NAD:arginine ADP-ribosyltransferase are provided herein. Recombinant protein is expressed from a recombinant gene vector containing at least 15 continuous bases of genes encoding these sequences.
Modified Defensins And Their Use
US Patent:
7511015, Mar 31, 2009
Filed:
Feb 18, 2003
Appl. No.:
10/504838
Inventors:
Joel Moss - Bethesda MD, US
Rodney L. Levine - Rockville MD, US
Akihiro Wada - Nagasaki, JP
Toshiya Hirayama - Nagasaki, JP
Gregorino Paone - Rome, IT
Rodney L. Levine - Rockville MD, US
Akihiro Wada - Nagasaki, JP
Toshiya Hirayama - Nagasaki, JP
Gregorino Paone - Rome, IT
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/00, A61K 38/19, C07K 14/00, C07K 14/52, C07K 1/107
US Classification:
514 12, 530350, 530351, 530402, 424 851
Abstract:
This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method is provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
Methods For Suppressing An Immune Response Or Treating A Proliferative Disorder
US Patent:
2012003, Feb 16, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/241008
Inventors:
Joel Moss - Bethesda MD, US
Arnold Kristof - Montreal, CA
Arnold Kristof - Montreal, CA
International Classification:
A61K 39/00, A61P 37/06, A61P 29/00, A61K 39/395, A61P 37/00
US Classification:
4241441, 4241841
Abstract:
Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure ofwherein the presence of each of Rand Ris optional and Rand Rare each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.